Contact
searchSearch
HMP Global
Login

Breast Cancer News

News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways
News
The Economic Impact of Artificial Intelligence Usage in Screening Mammography
05/10/2024
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the potential economic impact of artificial intelligence (AI) implementation on screening mammography from the perspective of treatment facilities and payers.
Researchers evaluated the...
05/10/2024
Journal of Clinical Pathways
News
Capivasertib Plus Palbociclib and Fulvestrant Demonstrated Safety, Tolerability Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
01/16/2024
Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.
Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.
Updated phase 1b results from...
01/16/2024
Oncology
News
Comparing Sacituzumab Govitecan and Physician’s Choice Treatment in HR+/HER2- Metastatic Breast Cancer: TROPiCS-02 Phase 3 Study Analysis
12/06/2023
Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...
Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...
Aditya Bardia, MD, and...
12/06/2023
Journal of Clinical Pathways
News
Study Explores the Cost-Effectiveness of Ultra-Hypofractionated Whole Breast Radiation Therapy vs Endocrine Therapy Alone vs Combination Therapy
02/14/2023
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction ultra-hypofractionated whole-breast irradiation (U-WBI) monotherapy seems to be the more cost-effective therapy approach when compared to monotherapy hormone monotherapy, according to results from a recent cost-utility...
The use of 5-fraction...
02/14/2023
Journal of Clinical Pathways
News
Guideline Update on Use of Biomarkers for Adjuvant Endocrine and Chemotherapy in Breast Cancer
07/08/2022
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the American Society of Clinical Oncology used informal consensus to develop updated recommendations on the appropriate use of breast cancer biomarker assay results to guide decisions about using adjuvant...
A panel of expert members of the...
07/08/2022
Journal of Clinical Pathways
News
Analyzing Experiences in Non-Medical Switching to Trastuzumab Biosimilars Among Oncologists and Patients With Breast Cancer
06/12/2022
Study findings suggest that there is a need for tailored patient and oncologist information and education on trastuzumab biosimilars, as well as improved health care communication regarding switching.
Study findings suggest that there is a need for tailored patient and oncologist information and education on trastuzumab biosimilars, as well as improved health care communication regarding switching.
Study findings suggest that...
06/12/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy
06/09/2022
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark...
06/09/2022
Journal of Clinical Pathways
News
Breast Conservation Yields Equal QOL Outcomes to Mastectomy and Reconstruction Among Patients With Breast Cancer
05/17/2022
A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.
A comparative effectiveness study showed that patients with early–stage breast cancer had similar quality of life outcomes after breast-conserving surgery with RT and after mastectomy and reconstruction without RT.
A comparative effectiveness...
05/17/2022
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use